| Title | Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance |
| Authors | Zhang, Jingru Wang, Yingqiao Wang, Jianxiang Hu, Jianda Chen, Suning Jin, Jie Liu, Ting Zhou, Jianfeng Hu, Yu Ma, Daoxin Huang, Xiaojun Ji, Chunyan Hou, Ming |
| Affiliation | Shandong Univ, Qilu Hosp, Dept Hematol, Jinan, Shandong, Peoples R China. Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China. Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China. Peking Union Med Coll, Tianjin, Peoples R China. Fujian Med Univ Union Hosp, Fujian Inst Hematol, Fujian Prov Key Lab Hematol, Fuzhou, Fujian, Peoples R China. Soochow Univ, Jiangsu Inst Hematol, Affiliated Hosp 1, Key Lab Thrombosis & Hemostasis,Minist Hlth, Suzhou, Jiangsu, Peoples R China. Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Coll Med, Hangzhou, Zhejiang, Peoples R China. Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Sichuan, Peoples R China. Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Hubei, Peoples R China. Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan, Hubei, Peoples R China. Peking Univ, Inst Hematol, Peoples Hosp, Beijing, Peoples R China. Shandong Univ, Qilu Hosp, Dept Hematol, Jinan, Shandong, Peoples R China. Huang, XJ (reprint author), Peking Univ, Inst Hematol, Peoples Hosp, Beijing, Peoples R China. |
| Keywords | PATIENTS RECEIVING IMATINIB EARLY MOLECULAR RESPONSE CHRONIC-PHASE FOLLOW-UP TRANSCRIPT LEVELS DASATINIB SAFETY ACHIEVEMENT MANAGEMENT PREDICTOR |
| Issue Date | 2018 |
| Publisher | BLOOD CANCER JOURNAL |
| Citation | BLOOD CANCER JOURNAL. 2018, 8. |
| Abstract | An early molecular response is spectacularly predictive of outcome in chronic myeloid leukemia (CML) and early response landmarks may identify the high-risk patients likely to be benefit from an early therapy switch. In this study, we evaluated the most relevant cutoffs for early molecular response markers (BCR-ABL1 values at 3 months, log reduction and halving time between diagnosis and 3 months) in 476 first-line imatinib-treated Chinese patients with chronic phase CML. All outcomes were significantly superior for the 324 patients with 3-month BCR-ABL1 <= 10%, so did for the 270 patients with BCR-ABL1 >0.61 log reduction. BCR-ABL1 halving time <= 22 days was identified for patients with the most favorable outcome. Moreover, the prognosis was significantly poorest for patients with both halving time >44 days and BCR-ABL1 >10%. Importantly, multivariate regression analysis demonstrated that a BCR-ABL1 log reduction calculated at 3 months of 0.61 was the only variable that significantly predicted for OS. Our results highlight the importance of rapid initial decline of BCR-ABL1 in predicting satisfactory outcome. Our data support the evidence that monitoring BCR-ABL1 values at an early time point could contribute to accurately assess response and ultimately guide clinical decisions regarding the timing of therapeutic intervention. |
| URI | http://hdl.handle.net/20.500.11897/523655 |
| ISSN | 2044-5385 |
| DOI | 10.1038/s41408-018-0093-4 |
| Indexed | SCI(E) |
| Appears in Collections: | 医学部待认领 |
